Abraxis BioScience (ABII)

Purchase Obligations

As of December 31, 2009, we purchased all of our approved paclitaxel supply from one supplier. We believe our supply risk with respect to this supplier is minimal given that the supplier is well-regarded within the industry and we have not historically experienced supply shortages with this supplier. Additionally, we maintain

83

Table of Contents

an adequate safety stock supply of paclitaxel to mitigate any supply disruption. As of December 31, 2009 and 2008, our inventory included $21.0 million and $34.4 million, respectively, of paclitaxel. As of December 31, 2009, we have no commitment agreement to purchase any paclitaxel in 2010.

We also have other material supply agreements that require us to purchase approximately $32.3 million of material supply in each of the next five years.

Purchase Obligations

As of December 31, 2008, we purchased all of our approved paclitaxel supply from one supplier. We believe our supply risk with respect to this supplier is minimal given that the supplier is well-regarded within the industry and we have not historically experienced supply shortages with this supplier. Additionally, we maintain an adequate safety stock supply of paclitaxel to mitigate any supply disruption. As of December 31, 2008 and 2007, our inventory included $34.4 million and $35.9 million, respectively, of paclitaxel. As of December 31, 2008, we have no commitment agreement to purchase any paclitaxel in 2009.

We also have other material supply agreements that require us to purchase approximately $26.6 million of material supply in each of the next five years.

Purchase Obligations

FACE="Times New Roman" SIZE="2">As of December 31, 2008, we purchased all of our approved paclitaxel supply from one supplier. We believe our supply risk with respect to this supplier is minimal given that the supplier is well-regarded within
the industry and we have not historically experienced supply shortages with this supplier. Additionally, we maintain an adequate safety stock supply of paclitaxel to mitigate any supply disruption. As of December 31, 2008 and 2007, our
inventory included $34.4 million and $35.9 million, respectively, of paclitaxel. As of December 31, 2008, we have no commitment agreement to purchase any paclitaxel in 2009.

Purchase Obligations

As of December 31, 2007, we purchased all of our approved paclitaxel supply from one supplier. We believe our supply risk with respect to this supplier is minimal given that the supplier is well-regarded within the industry and we have not historically experienced supply shortages with this supplier. Additionally, we maintain an adequate safety stock supply of paclitaxel to mitigate any supply disruption. As of December 31, 2007, our inventory included $35.9 million of paclitaxel (whole plant). As of December 31, 2007, we have a commitment agreement to purchase $3.5 million of paclitaxel in 2008.

We also have equipment supply agreements that requires us to purchase approximately $0.2 million of equipment in each of the next five years.

Purchase Obligations

FACE="Times New Roman" SIZE="2">As of December 31, 2007, we purchased all of our approved paclitaxel supply from one supplier. We believe our supply risk with respect to this supplier is minimal given that the supplier is well-regarded within
the industry and we have not historically experienced supply shortages with this supplier. Additionally, we maintain an adequate safety stock supply of paclitaxel to mitigate any supply disruption. As of December 31, 2007, our inventory
included $35.9 million of paclitaxel (whole plant). As of December 31, 2007, we have a commitment agreement to purchase $3.5 million of paclitaxel in 2008.

FACE="Times New Roman" SIZE="2">We also have equipment supply agreements that requires us to purchase approximately $0.2 million of equipment in each of the next five years.

FACE="Times New Roman" SIZE="2">Clinical Trial and Other Commitments

We have entered into various clinical trial agreements with
third parties for the management, planning and execution of clinical trials. These agreements generally include milestone payments based on the number of patients enrolled in the clinical study. If all milestones in these agreements were achieved,
related milestone commitments to be paid by us in 2008 through 2012 would approximate $29.8 million. Based on our current estimates of patient enrollment, approximately $17.3 million would be payable in 2008, approximately $7.1 million
would be payable in 2009, approximately $3.4 million would be payable in 2010, approximately $1.8 million would be payable in 2011 and approximately $0.2 million would be payable in 2012.

Purchase Obligations

As of December 31, 2006, New Abraxis purchased all of its paclitaxel supply from one supplier. New Abraxis believes its supply risk with respect to this supplier is minimal given that the supplier is well-regarded within the industry and New Abraxis has not historically experienced supply shortages with this supplier. Additionally, New Abraxis maintains an adequate safety stock supply of paclitaxel to mitigate any supply disruption. As of December 31, 2006, New Abraxis’ inventory included $17.7 million of paclitaxel (whole plant). As of December 31, 2006, New Abraxis had a commitment agreement to purchase $3.1 million of paclitaxel in 2007.